Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Report Summary

GlobalData, the industry analysis specialist, has released its new report, “Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Chronic Kidney Disease Therapeutics market. The report identifies the key trends shaping and driving the global Chronic Kidney Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Chronic Kidney Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts

Scope

The report provides information on the key drivers and challenges of the Chronic Kidney Disease Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Chronic Kidney Disease Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Chronic Kidney Disease Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Chronic Kidney Disease Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Chronic Kidney Disease Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Chronic Kidney Disease Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Chronic Kidney Disease Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What’s the next big thing in the global Chronic Kidney Disease Therapeutics market landscape? - Identify, understand and capitalize.

Table of Contents

1 Table of contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Signs and Symptoms
2.6 Diagnosis
2.7 Treatment and Management Pattern
2.7.1 Classification of the Causes of CKD
2.7.2 Drug Therapy
2.7.3 Dialysis
2.7.4 Kidney Transplantation
2.7.5 Treatment Flow of the Disease
2.8 GlobalData Pipeline Report Guidance

3 Chronic Kidney Disease Market - Market Characterization
3.1 Major Markets, Market Size (2005-2010)
3.2 Major Markets, Market Forecast (2010-2018)
3.3 CKD Therapeutics Market Size (2005-2010) - The US
3.4 CKD Therapeutics Market Forecast (2010-2018) - The US
3.5 CKD Therapeutics Market Size (2005-2010) - France
3.6 CKD Therapeutics Market Forecast (2010-2018) - France
3.7 CKD Therapeutics Market Size (2005-2010) - Germany
3.8 CKD Therapeutics Market Forecast (2010-2018) - Germany
3.9 CKD Therapeutics Market Size (2005-2010) - Italy
3.10 CKD Therapeutics Market Forecast (2010-2018) - Italy
3.11 CKD Therapeutics Market Size (2005-2010) - Spain
3.12 CKD Therapeutics Market Forecast (2010-2018) - Spain
3.13 CKD Therapeutics Market Size (2005-2010) - The UK
3.14 CKD Therapeutics Market Forecast (2010-2018) - The UK
3.15 CKD Therapeutics Market Size (2005-2010) - Japan
3.16 CKD Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Chronic Kidney Disease Therapeutics Market
3.17.1 Drivers for the Chronic Kidney Disease Therapeutics Market
3.17.2 Barriers for the Chronic Kidney Disease Therapeutics Market
3.18 Opportunity and Unmet Need
3.18.1 Opportunity and Unmet Need for the Phosphate Binders Class in the CKD Market
3.18.2 Opportunity and Unmet Need for the Anti-Hypertensives and Anti-Diabetics Class in the CKD Market
3.18.3 Opportunity and Unmet Need for the Immunosuppressants, Corticosteroids and Antibiotics Class in the CKD Market
3.19 Key Takeaway

4 Chronic Kidney Disease Market - Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.1.2 Competitor Assessment Within the Classes Considered in the Treatment of CKD
4.2 Chronic Kidney Disease Market - Marketed Product Profiles
4.2.1 Renagel (sevelamer hydrochloride)
4.2.2 Renvela (sevelamer carbonate)
4.2.3 Fosrenol (lanthanum carbonate hydrate)
4.2.4 Phoslo Gelcaps
4.2.5 Antihypertensive Agents
4.2.6 Immunosuppressants
4.2.7 Corticosteroids
4.2.8 Antibiotics
4.3 Key Takeaway

5 Chronic Kidney Disease Market - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Chronic kidney Disease Pipeline Analysis - Pipeline by Clinical Phases of Development
5.3.1 CKD Therapeutics - NDA Filed
5.3.2 CKD Therapeutics - Phase III Clinical Pipeline
5.3.3 CKD Therapeutics - Phase II Clinical Pipeline
5.3.4 CKD Therapeutics - Phase I Clinical Pipeline
5.3.5 CKD Therapeutics - Preclinical and Discovery Pipeline
5.4 Chronic Kidney Disease Pipeline by Mechanism of Action
5.5 Chronic Kidney Disease Technology Trends Analytical Framework
5.6 Chronic Kidney Disease, Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs Under Clinical Development
5.7.1 Bixalomer (ASP 1585, AMG223, ILY101)
5.7.2 Kremezin (AST-120, MP-146)
5.7.3 Bardoxolone methyl (RTA 402)
5.7.4 Sensipar/Mimpara (cinacalcet hydrochloride)
5.7.5 Colestilan (MCI-196)
5.7.6 PA21
5.7.7 Beraprost Sodium (YM533)
5.7.8 Zerenex (ferric citrate, KRX-0502)
5.8 Key Takeaway

6 Chronic Kidney Disease Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials Mapping by Region/Country
6.2 Clinical Trials Mapping by Phase
6.3 Clinical Trials Mapping by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Participants in Therapeutic Clinical Trials - Companies

7 Chronic Kidney Disease Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario

8 Global Chronic Kidney Disease - Future Players in the Market
8.1 Introduction
8.2 Company Profiles
8.2.1 Amgen Inc.
8.2.2 Mitsubishi Tanabe Pharma Corporation
8.2.3 Galenica Ltd.
8.2.4 Astellas Pharma Inc
8.2.5 Reata Pharmaceuticals Inc.
8.2.6 Keryx Biopharmaceuticals
8.3 Other Companies in the Pipeline - Tabular Presentation

9 Licensing, Partnership and Acquisition Deals

10 Global Chronic Kidney Disease Market - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Sources

List of Tables

Table 1: Prevalence of CKD
Table 2: Stages of Chronic Kidney Disease
Table 3: Dialysis Solutions
Table 4: CKD Therapeutics, Major Markets, Market Revenue ($bn), 2005-2010
Table 5: CKD Therapeutics, Global, Revenue Forecasts ($bn), 2010-2018
Table 6: CKD Therapeutics, the US, Market Historical Revenue ($bn), 2005-2010
Table 7: CKD Therapeutics, the US, Revenue Forecasts ($bn), 2010-2018
Table 8: CKD Therapeutics, France, Market Historical Revenue ($m), 2005-2010
Table 9: CKD Therapeutics, France, Revenue Forecasts ($m), 20010-2018
Table 10: CKD Therapeutics, Germany, Market Revenue ($m), 2005-2010
Table 11: CKD Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018
Table 12: CKD Therapeutics, Italy, Market Revenue ($m), 2005-2010
Table 13: CKD Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018
Table 14: CKD Therapeutics, Spain, Market Revenue ($m), 2005-2010
Table 15: CKD Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018
Table 16: CKD Therapeutics, the UK, Market Revenue ($m), 2005-2010
Table 17: CKD Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018
Table 18: CKD Therapeutics, Japan, Market Revenue ($m), 2005-2010
Table 19: CKD Therapeutics, Japan, Revenue Forecasts ($m), 2010-2018
Table 20: CKD Therapeutics - NDA Filed, 2011
Table 21: CKD Therapeutics - Phase III Clinical Pipeline, 2011
Table 22: CKD Therapeutics - Phase II Clinical Pipeline, 2011
Table 23: CKD Therapeutics - Phase I Clinical Pipeline, 2011
Table 24: CKD Therapeutics - Preclinical Pipeline, 2011
Table 25: Mechanisms of Action that Constitute ‘Others’ in the Above Pie Chart
Table 26: CKD Therapeutics - Promising Drugs Under Clinical Development, 2011
Table 27: CKD Therapeutics - Clinical Trials by Region, 2011
Table 28: CKD Therapeutics - Clinical Trials by Phase, 2011
Table 29: CKD Therapeutics - Clinical Trials by Region, 2011
Table 30: CKD Therapeutics - Clinical Trials by Sponsor, 2011
Table 31: CKD Therapeutics - Clinical Trials by Sponsors, 2011
Table 32: Amgen Inc - CKD Pipeline, 2011
Table 33: Amgen Inc. - Deals
Table 34: Mitsubishi Tanabe - Genitourinary System and Sex Hormones Pipeline, 2011
Table 35: Mitsubishi Tanabe - CKD Pipeline, 2011
Table 36: Mitsubishi Tanabe Corporation Deals, 2011
Table 37: Galenica Therapeutic - CKD Pipeline, 2011
Table 38: Galenica Ltd - Deals, 2011
Table 39: Astellas Pharma - Genitourinary System and Sex Hormones Pipeline, 2011
Table 40: Astellas Pharma - CKD Therapeutics Pipeline, 2011
Table 41: Astellas Pharma - Deals, 2011
Table 42: Reata Pharmaceuticals Inc - CKD Therapeutic Pipeline, 2011
Table 43: Reata Pharmaceuticals Inc - Deals, 2011
Table 44: Keryx Biopharmaceuticals - CKD Therapeutics Pipeline, 2011
Table 45: Keryx Biopharmaceuticals - Deals, 2011
Table 46: Other Companies that have Molecules for CKD in the Pipeline
Table 47: CKD Therapeutics, Licensing and Partnership Deals

List of Figures

Figure 1: Common Causes of CKD
Figure 2: Hemodialysis
Figure 3: Peritoneal Dialysis
Figure 4: Kidney Transplantation
Figure 5: CKD Treatment Flow, 2011
Figure 6: CKD Therapeutics, Major Markets, Market Revenue ($bn), 2005-2010
Figure 7: CKD Therapeutics, Market Share ($m, %), 2010
Figure 8: CKD Therapeutics, Major Markets, Revenue Forecasts ($bn), 2010-2018
Figure 9: CKD Therapeutics, Forecast Market Share ($m, %), 2018
Figure 10: CKD Therapeutics, the US, Market Revenue ($bn), 2005-2010
Figure 11: CKD Therapeutics, the US, Revenue Forecasts ($bn), 2010-2018
Figure 12: CKD Therapeutics, France, Market Revenue ($m), 2005-2010
Figure 13: CKD Therapeutics, France, Revenue Forecasts ($m), 2010-2018
Figure 14: CKD Therapeutics, Germany, Market Revenue ($m), 2005-2010
Figure 15: CKD Therapeutics, Germany, Revenue Forecasts ($m), 2010-2018
Figure 16: CKD Therapeutics, Italy, Market Revenue ($m), 2005-2010
Figure 17: CKD Therapeutics, Italy, Revenue Forecasts ($m), 2010-2018
Figure 18: CKD Therapeutics, Spain, Market Revenue ($m), 2005-2010
Figure 19: CKD Therapeutics, Spain, Revenue Forecasts ($m), 2010-2018
Figure 20: CKD Therapeutics, the UK, Market Revenue ($m), 2005-2010
Figure 21: CKD Therapeutics, the UK, Revenue Forecasts ($m), 2010-2018
Figure 22: CKD Therapeutics, Japan, Market Revenue ($m), 2005-2010
Figure 23: CKD Therapeutics, Japan, Revenue Forecasts ($m), 2010-2018
Figure 24: Opportunity and Unmet Need for the Phosphate Binders Class in the CKD Market, 2011
Figure 25: Opportunity and Unmet Need for the Anti-Hypertensives and Anti-Diabetics Class in the CKD Market, 2011
Figure 26: Opportunity and Unmet Need for the Immunosuppressants, Corticosteroids and Antibiotics Class in the CKD Market, 2011
Figure 27: Strategic Competitor Assessment of the Phosphate Binders Class in the CKD Therapeutics Market, 2011
Figure 28: Strategic Competitor Assessment of the Anti-Hypertensives and Anti-Diabetics Class in the CKD Therapeutics Market, 2011
Figure 29: Strategic Competitor Assessment of the Immunosuppressant, Corticosteroid and Antibiotic Classes in the CKD Therapeutics Market, 2011
Figure 30: CKD Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 31: CKD Therapeutics - Clinical Pipeline by Mechanism of Action, 2011
Figure 32: CKD Therapeutics - Technology Trends Analytical Framework for the CKD Pipeline, 2011
Figure 33: CKD Therapeutics - Technology Trends Analytical Framework for the CKD Pipeline - Description, 2011
Figure 34: CKD Therapeutics - Clinical Trials by Region, 2011
Figure 35: CKD Therapeutics - Clinical Trials by Phase, 2011
Figure 36: CKD Therapeutics - Clinical Trials by Status, 2011
Figure 37: CKD Therapeutics - Clinical Trials by Overall Sponsors, 2011
Figure 38: CKD Therapeutics - Clinical Trials by Prominent Sponsors, 2011
Figure 39: Top Companies Participating in CKD Therapeutics Clinical Trials, 2011
Figure 40: CKD Therapeutics - Key Events Impacting the Future Market, 2011
Figure 41: CKD Therapeutics - Strategic Assessment, 2011
Figure 42: CKD Therapeutics, Clinical Pipeline by Company, 2011
Figure 43: GlobalData Market Forecasting Model